Sort
39,280 grants matching “leukemia”
Role of the pre-T cell receptor in lineage commitment
$372,015Harald Von Boehmer · Dana-Farber Cancer Inst · R01 · FY2007 · AI
Molecular Immunology of Minor Histocompatibility Antigen
$372,015Sebastian Joyce · Vanderbilt University · R01 · FY2007 · HL
Exposure Insights Using GIS in a Case-Control Study
$372,013Impact Assessment, Inc. · R01 · FY2004 · CA
Core A: Single Cell Profiling and Bioinformatics Core
$372,000Koichi Takahashi · Baylor College Of Medicine · P01 · FY2023 · CA
Mechanisms of autoinhibition and activation of the Abl kinase
$372,000Charalampos Kalodimos · Rutgers, The State Univ Of N.J. · R01 · FY2014 · GM
MicroRNA Regulates Graft-versus-Host Disease
$371,988Xue-Zhong Yu · Medical University Of South Carolina · R01 · FY2017 · AI
LFM-A13: An antileukemic/antithrombotic agent
$371,950Paradigm Pharmaceuticals, Llc · R44 · FY2004 · HL
Mechanisms of differentiation blockade in CSF3R-mutant AML
$371,948Julia E Maxson · Oregon Health & Science University · R01 · FY2023 · CA
SPORE in Lymphoma
$371,941Helen E Heslop · Baylor College Of Medicine · P50 · FY2009 · CA
PHASE I TRIALS OF ANTICANCER AGENTS
$371,938University Of Maryland Baltimore · U01 · FY2002 · CA
Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers
$371,925Matthias Stephan · Fred Hutchinson Cancer Research Center · R01 · FY2017 · CA
Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers
$371,925Matthias Stephan · Fred Hutchinson Cancer Research Center · R01 · FY2018 · CA
Structural Biology of AML1 (CBFA2) and AML1-ETO
$371,924University Of Virginia Charlottesville · R01 · FY2004 · CA
IDENTIFICATION OF TARGETS OF BCR ABL IN THE LEUKEMOGENIC
$371,904Brandeis University · R01 · FY2003 · CA
Targeting the APC/Cdc20 E3 ubiquitin ligase for chemoradiation sensitization
$371,883Wenyi Wei · Beth Israel Deaconess Medical Center · R01 · FY2019 · CA
Role of cross-presentation by APCs in modulating graft-versus-leukemia responses
$371,870Pavan Reddy · University Of Michigan At Ann Arbor · R01 · FY2011 · HL
Optimizing demethylating therapy for IDH1 Mutant Malignant Gliomas
$371,863Gregory Joseph Riggins · Johns Hopkins University · R01 · FY2024 · CA
The Core Apoptotic Pathway Controlling Glucocorticoid-induced Apoptosis in ALL
$371,859Scott A Armstrong · Dana-Farber Cancer Inst · P01 · FY2010 · CA
ABT-199 based therapies to treat neuroblastoma
$371,856Anthony Charles Faber · Virginia Commonwealth University · R01 · FY2017 · CA
Elucidating the AKT-dependent and AKT-independent mechanisms of metabolic control by mTORC2
$371,816David A Guertin · Univ Of Massachusetts Med Sch Worcester · R01 · FY2017 · CA
Biomarkers of Formaldehyde Exposure and Toxicity
$371,805Luoping Zhang · University Of California Berkeley · R01 · FY2009 · ES
Mutational and biochemical analysis of Fgd2 and Fgd3
$371,799Amanda L Gavin · Scripps Research Institute, The · R01 · FY2008 · AI
Mutational and biochemical analysis of Fgd2 and Fgd3
$371,799Amanda L Gavin · Scripps Research Institute, The · R01 · FY2009 · AI
Peptide-directed protocells and virus-like particles-new nanoparticle platforms f
$371,721Cheryl L Willman · University Of New Mexico Health Scis Ctr · U01 · FY2011 · CA
Genomics of AML Prognosis
$371,709Jatinder K. Lamba · University Of Florida · R01 · FY2022 · CA